Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 4th Preview)
-
FDA clears first-of-its-kind campus-developed CAR T for IND review
The University of Colorado Anschutz Gates Institute received U.S. FDA Investigational New Drug (IND) clearance for a novel CAR T-cell therapy, marking the first time the agency has cleared a CAR T platform developed entirely within a U.S. university setting. The development represents a regulatory milestone for academic manufacturing and translation of cellular immunotherapies. For biotech operators, the filing underscores how CAR T capabilities are spreading beyond traditional industrial CDMOs and large clinical networks. It also raises attention on what data packages universities can assemble for safety, quality, and clinical readiness at IND stage. While specific target antigens and trial identifiers were not included in the brief, the clearance itself signals the FDA’s acceptance of the university’s supporting chemistry, manufacturing, and controls strategy for a next-generation program.
-
Epigenetic reactivation of a tumor suppressor re-frames AML biology
Researchers at The Jackson Laboratory (JAX) and collaborators identified an epigenetic strategy to restore the tumor suppressor ZBTB7A in acute myeloid leukemia (AML) models. Their mouse data, published in Science Translational Medicine, show that inhibiting KDM4 can reactivate ZBTB7A expression and reduce leukemia burden. The team used a mapping tool combining fluorescence in situ hybridization and flow cytometry with CRISPR gene editing (FISHnCRISP) to pinpoint ZBTB7A silencing. Mechanistically, the authors link a longer ZBTB7A regulatory tail to ZFP36L2-mediated repression and connect the suppression to KDM4’s DNA packaging effects. Importantly, blocking KDM4 improved leukemia outcomes while largely preserving normal blood formation in the study’s experiments. The work also adds a generalizable approach for identifying gene-silencing mechanisms that are missed by mutation-first sequencing.
-
Manufacturing surge for immune checkpoint oncology: Lonza to supply PD-L1 antibody
ImmuneOncia Therapeutics and Lonza signed an agreement for late-stage clinical manufacturing of Danburstotug (IMC-001), a fully human PD-L1 immune checkpoint antibody in development for relapsed/refractory NK/T-cell lymphoma. Lonza will support both drug substance and clinical drug product supply across its UK, Switzerland, and Basel/Stein sites. The collaboration aims to position the program for early regulatory momentum in a rare cancer indication while leveraging Lonza’s end-to-end development and manufacturing infrastructure. Danburstotug’s route through late-stage clinical supply highlights how contract manufacturers are increasingly central to oncology program timelines. For the broader biotech ecosystem, the deal signals ongoing demand for integrated biologics manufacturing capacity as companies push toward global clinical execution.
-
Oncology supportive care: COCOON trial reports 50% dermatologic toxicity reduction
Interim results from the phase II COCOON trial show a proactive skincare approach can cut dermatologic adverse events by 50% in patients receiving frontline therapy for EGFR-mutant non-small cell lung cancer (NSCLC). The study, led by Bishal Tiwari of Nassau University Medical Center and Asmita… (as reported), frames the interim readout as a practical mitigation strategy during EGFR inhibitor treatment. Dermatologic toxicities are among the most common dose-limiting issues in EGFR-mutant NSCLC regimens, and they can drive treatment interruptions or dose modifications. A 50% reduction in such events, if confirmed in later analyses, would position supportive care as a meaningful lever for maintaining dose intensity. The trial’s interim nature suggests continued data collection ahead of any definitive practice guidance, but the reported magnitude makes it stand out for oncology operations and patient management workflows.
-
TriNetX and Regeneron expand data linkage for discovery and development
TriNetX will link and provide Regeneron exclusive access to de-identified genomic and proteomic data for drug discovery and development. The agreement gives Regeneron secure, licensed access to TriNetX’s current and future de-identified health data from roughly 300 million individuals. The move targets multi-modal learning pipelines where outcomes and biology need to be connected at scale—particularly useful for target discovery, translational biomarker development, and clinical development planning. It also reflects how large-scale real-world datasets are increasingly treated as core “wet-lab adjacent” infrastructure. For biotech decision-makers, the key operational angle is exclusivity and forward-looking coverage (current and future data), which can matter for long-term model-building and program iteration.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.